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Abstract
Background: Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized
by inflammatory serositis (fever, peritonitis, synovitis and pleuritis). The gene locus responsible for
FMF was identified in 1992 and localized to the short arm of chromosome 16. In 1997, a specific
FMF gene locus, MEFV, was discovered to encode for a protein, pyrin that mediates inflammation.
To date, more than forty missense mutations are known to exist. The diversity of mutations
identified has provided insight into the variability of clinical presentation and disease progression.
Case Report: We report an individual heterozygous for the M680I gene mutation with a clinical
diagnosis of FMF using the Tel-Hashomer criteria. Subsequently, the patient developed nephrotic
syndrome with biopsy-confirmed fibrillary glomerulonephritis (FGN). Further diagnostic studies
were unremarkable with clinical workup negative for amyloidosis or other secondary causes of
nephrotic syndrome.
Discussion: Individuals with FMF are at greater risk for developing nephrotic syndrome. The most
serious etiology is amyloidosis (AA variant) with renal involvement, ultimately progressing to end-
stage renal disease. Other known renal diseases in the FMF population include IgA nephropathy,
IgM nephropathy, Henoch-Schönlein purpura as well as polyarteritis nodosa.
Conclusion: To our knowledge, this is the first association between FMF and the M680I mutation
later complicated by nephrotic syndrome and fibrillary glomerulonephritis.
Background
Familial Mediterranean Fever (FMF) is an autosomal
recessive disease primarily affecting individuals of Arme-
nian, Turkish, Arab, and Jewish origin [1]. The disease is
characterized by recurrent episodes of fever, pleuritis, peri-
tonitis, synovitis, and pericarditis [2–4]. The most serious
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complication of FMF is the development of amyloidosis
(AA variant), leading to nephrotic syndrome and end-
stage renal disease [4]. Amyloidosis remains the leading
cause of FMF-related mortality in affected individuals not
receiving colchicine prophylaxis [5]. Additionally, other
non-amyloid renal diseases are reported to occur in the
FMF population with variable prevalence; for example,
IgA and IgM nephropathy, and vasculitides including
both polyarteritis nodosa (PAN) and Henoch-Schonlëin
purpura [6]. Differentiation of the underlying renal dis-
ease in FMF patients who present with nephrotic syn-
drome is difficult, often requiring further diagnostic
studies to identify the etiology. Moreover, the identifica-
tion of the etiology of nephrotic syndrome is critical in
determining an effective treatment regimen. For example,
patients with amyloidosis (AA variant) usually respond to
oral colchicine, which is known to prevent the insidious
onset of end-stage renal disease [5]. In contrast, patients
with PAN or Henoch-Schonlëin purpura usually respond
very well to corticosteroids, with some experiencing com-
plete resolution of proteinuria. [6]
In 1992, the gene responsible for Familial Mediterranean
Fever (FMF), MEFV, was found to reside on the short arm
of chromosome 16 [7]. Five-years later, the MEFV gene
locus was discovered to encode for a protein, pyrin
(marenostrin), a member of the RoRet gene family [8,9].
Pyrin is known to play a role in mitigating an inflamma-
tory response [8,10]. To date, more than forty missense
mutations are noted in association with FMF. One specific
mutation, M694V, has been implicated as a risk factor for
amyloidosis, especially in North African Jews
homozygous for the M694V missense mutation [11].
However, individuals with mutations other than M694V
are known to develop amyloidosis with renal involve-
ment [11]. For the first time, we report an individual with
symptomatic FMF, heterozygous for the M680I missense
mutation, who developed progressive proteinuria, hema-
turia, and subsequent nephrotic syndrome secondary to
fibrillary glomerulonephritis.
Case Report
A forty-nine year-old American man of Armenian ancestry
was diagnosed clinically with Familial Mediterranean
Fever (FMF) at age 39. At that time, he presented with
recurrent, episodic fevers, peritonitis, synovitis, and pleu-
ritis. Since the initial diagnosis, his treatment consisted of
oral colchicine (1.2 mg/day), resulting in a decrease in the
frequency, duration, and intensity of his inflammatory
episodes. However, over the subsequent decade, his
inflammatory episodes became more frequent, occurring
every 7–10 days, with an average duration of approxi-
mately 3 days. His symptoms consisted of diffuse abdom-
inal pain, sharp, non-radiating chest pain, and fevers as
high as 103 degrees F. An extensive workup for other eti-
ologies responsible for febrile illness was unremarkable
(e.g. infection, malignancy, connective tissue disorders).
Upon further examination, the previous diagnosis of FMF
was confirmed using the Tel-Hashomer criteria [12].
Despite an increase in the oral colchicine dose to 1.8 mg/
day, his symptoms persisted, prompting further diagnos-
tic studies to correlate the clinical diagnosis with geno-
type. A serum sample was sent to the UCLA Medical
Center for genetic analysis. Polymerase chain reaction,
testing for the nine most common mutations [Table 1],
was performed by methods previously described [13]. The
results demonstrated the presence of an MEFV missense
mutation (M680I) on one allele. Several months later, he
presented with complaints of lower extremity edema
without associated symptoms of cough, shortness of
breath, dyspnea on exertion, orthopnea, paroxysmal noc-
turnal dyspnea, or chest pain. Upon further questioning,
the patient admitted to gradual development of lower
extremity edema over the past 2 to 3 months. He denied
complaints of dysuria, polyuria, hematuria, or any discol-
oration of his urine. The remainder of the review of sys-
tems was unremarkable. A 2-dimensional
echocardiogram revealed a normal size heart, normal val-
vular structure and function, and preserved left ventricular
systolic function with a left ventricular ejection fraction of
55–60 percent. Relevant serological studies were con-
ducted to evaluate the etiology of nephrosis. In addition
to a urinalysis, the urine protein and creatinine were
measured. Results from the urinalysis were positive for
proteinuria (3+) and red blood cells (50–100 RBC's/
HPF). The spot urine protein/creatinine ratio was 4.0. The
patient's blood urea nitrogen (BUN) and serum creatinine
were 17 mg/dl and 0.9 mg/dl, respectively. Erythrocyte
sedimentation rate was 72 mm/hr with a normal com-
plete blood count and differential. Serological tests for
HIV (types I and II), HIV p24 antigen, Hepatitis A, B, and
C titers were negative. Furthermore, tests for ANA, RPR,
rheumatoid factor, c-ANCA, p-ANCA, cryoglobulin, lupus
anticoagulant and anticardiolipin antibodies were nega-
tive. Both C3 and C4 complement levels were within nor-
Table 1: MEFV missense mutations evaluted in our patient
Exon 2 Exon 10
E148Q M680I
M694V
M694I
692delI
LS95R
A744S
V726A
* Analysis performed at the UCLA Medical Center using Polymerase 
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mal limits. Additionally, serum protein electrophoresis
was negative for a monoclonal gammopathy. The kappa/
lambda ratio was 1.93 (NML range: 1.47–2.95). Urine
protein electrophoresis was also unremarkable without
evidence of Bence-Jones proteins.
As a result of the clinical and diagnostic findings consist-
ent with nephrotic syndrome, a renal biopsy was per-
formed. Biopsy results demonstrated sclerosis of
approximately one-third of the glomeruli. The remaining
glomeruli were hypercellular, exhibiting both mesangial
and epithelial hyperplasia. Deposition of homogenous
eosinophilic material was noted in capillary walls and
mesangial areas, and stains for Congo red, thioflavin T
and amyloid AA protein were all negative. Direct immun-
ofluorescence showed a linear pattern of staining for IgG
and C3, with equal staining for kappa and lambda light
chains. Electron microscopy showed accumulation of
fibrillary material in mesangial areas and capillary base-
ment membranes [Figures 1, 2]. The individual fibrils
averaged 15–20 nm in diameter. In light of the noncon-
gophilic staining and fibril size, a diagnosis of fibrillary
glomerulonephritis was rendered.
Discussion
Once regarded simply as an inflammatory, autosomal
recessive disease of unknown etiology, the spectrum of
FMF has evolved as a complex genetic puzzle during the
genomic era. More than forty missense mutations result-
ing in abnormal pyrin proteins have led to a new para-
Renal biopsy (Light Microscopy) Figure 1
Renal biopsy (Light Microscopy). Light microscopy image of a glomerulus demonstrating negative staining for both Congo-
red and thioflavin-T. Expansion of the mesangium with increased hyalinization of the basement membrane (arrow) and thicken-
ing capillary loops is present.BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/6
Page 4 of 7
(page number not for citation purposes)
digm for FMF as an inherited state of dysregulated
inflammation. The altered gene products – the so-called
pyrins – are fundamental to understanding FMF. Pyrin-
containing proteins play a pivotal role in the immune
response by serving as key inflammatory mediators.
Unsurprisingly, pyrin is found in large quantities in neu-
trophils and released in response to inflammatory stimuli.
Additionally, a recently discovered pyrin-like domain was
found to exist at the amino-terminal of several proteins
involved in cell-signaling pathways inherent to inflamma-
tion. One pyrin protein, belonging to a larger class of the
pyrin domain family, is involved in the Nuclear Factor-
kappa B (NF-kB) cell-signaling pathway. Nuclear Factor-
kappa B is an important transcription factor involved in
inflammation via its induction of pro-inflammatory gene
products. In individuals with the "wild-type" MEFV gene,
pyrin serves a key role in regulating the intensity of the
inflammatory response. In contrast, individuals with one
or more missense mutations at the MEFV locus produce a
pyrin protein with altered or absent function. Conse-
quently, the response to inflammation is altered. The
resultant dysregulated inflammatory response often times
exceeds physiologic parameters and is disproportionate to
the insult. [18–22]
The inflammation of FMF may not only be characterized
as dysregulated, but is also chronic and recurrent. Its
severity and duration have been associated with the sec-
ondary development of amyloidosis (AA variety). The
amyloid fibrils that lead to nephrotic syndrome in FMF
Fibrillary Glomerular Deposition (Electron Microscopy) Figure 2
Fibrillary Glomerular Deposition (Electron Microscopy). Electron micrograph of renal biopsy showing randomly 
arranged microfibrils (asterisks) measuring 15–20 nm in diameter located in the basement membrane and mesangium.BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/6
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are derived from a serum precursor, serum amyloid A
(SAA), itself the result of chronic inflammation. Amy-
loidosis, with renal involvement and nephrotic syn-
drome, has become the expected complication of long-
term FMF. [14–17]
The novel association between FMF and fibrillary glomer-
ulopathy in this patient raises two contingent questions.
First, is the association itself a chance one, but if it is not,
is fibrillary glomerulopathy like amyloidosis the result of
material deposition that reflects chronic, dysregulated
inflammatory activity? The present state of knowledge
regarding fibrillary glomerular diseases strongly suggests
that the presence of fibrils in the glomeruli of affected
individuals represents fibrillar derivation from circulating
immunologic molecules, fragments, or immune com-
plexes [14]. Since their etiology, deposition and structure
are analogous to that of amyloid in FMF, it is highly
intriguing to postulate that this patient's renal involve-
ment is more than a chance occurrence. Prior disease asso-
ciations with the fibrillary glomerulopathies involve the
presence of immune response-associated products
[14,15]. Future reports of individuals or kindred with
FMF, nephrotic syndrome and fibrillary glomerulopathy
will be required to substantiate our theory.
M680I Missense Mutation Figure 3
M680I Missense Mutation. Illustration of the unspliced MEFV gene locus with exons 1–10 depicted (a), the spliced mRNA 
transcript revealing exon 2 and exon 10 and their respective codon number identifying where the nine most common muta-
tions for FMF have been identified (b); a diagram illustrating the derivation of the M680I mutation from exon 10 with the amino 
acid methionine (wild-type) substituted with isoleucine at codon 680 (c).
MEFV GENE LOCUS MEFV GENE LOCUS
3 5 6 9 8 10 1 4 7 2
680-761 148
M680I
METHIONINE ISOLEUCINE
Amino Acid Substitution Amino Acid Substitution
(b)
(a)
(c)
1 761BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/6
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Conclusions
Although the association between chronic inflammation
and amyloidosis (AA) is well known, the present descrip-
tion of fibrillary glomerulopathy in FMF requires further
elucidation. Nevertheless, the new association among
FMF, nephrotic syndrome, fibrillary glomerulopathy, and
an M680I (Figure 3) heterozygous genotype may repre-
sent a novel renal complication of FMF. Furthermore, it is
suggested that symptomatic heterozygous individuals
may actually be compound heterozygotes for a mutation
not yet identified [22]. As the number of MEFV mutations
discovered continues to increase, more data will become
available revealing further relationships among the many
different MEFV missense mutations and their phenotypic
expression in various ethnic groups.
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